1. Sweden Stocks

  2. •

    Healthcare

  3. •

    Medical - Devices
Getinge AB (publ)

Getinge AB (publ)

GETI-B.ST
Getinge AB (publ)SE flagStockholm Stock Exchange
206.00
SEK
+0.10
- -
56.11BMarket Cap
Getinge AB (publ)
GETI-B.ST
(Stockholm Stock Exchange)

Recent

price

206.00

P/E

ratio

- -

div

yld

- -

ROIC.AI

2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
FRC
87.71
86.46
95.93
100.04
105.5
119.61
91.7
89.72
88.75
97.51
109.48
99.31
103.87
116.85
127.62
128.38
130.33
Revenue per Share
9.01
10
9.97
9.04
5.67
5.5
4.91
5.49
-3.55
4.49
11.89
10.9
9.15
8.86
6.01
8.29
5.47
Basic EPS, GAAP
11.32
8.85
7.84
7.36
10.2
6.76
9.29
4.39
9.19
9.59
22.59
20.67
8.19
5.89
12
9.67
9.93
Free Cash Flow per Basic Share
2.59
3.07
3.54
3.91
3.93
2.73
2.83
1.97
1.56
1.09
1.59
3.15
4.08
4.34
4.5
4.65
4.68
Dividend per Share
32.27
39.65
44.98
49.7
49.59
52.38
56.22
49.57
41.04
43.11
53.45
61.37
69.51
73.42
75.13
79.45
73.76
Book Value per Share
-23.64
-39.01
-38.35
-33.89
-44.98
-43.32
-45.86
-12.92
-16.31
-12.15
-2.2
3.77
12.64
-0.98
-22.14
-14.76
-20.82
Tangible Book Value per Share
253
253
253
253
253
253
242
251
272
272
272
272
272
272
272
272
272
Basic Weighted Avg Shares
22,172
21,854
24,248
25,287
26,669
30,235
22,170
22,495
24,172
26,559
29,819
27,049
28,291
31,827
34,759
34,968
35,499
Sales/Revenue/Turnover
17.45
18.76
17.46
16.46
14.42
11.31
12.08
10.03
-1.17
10.19
16.87
16.07
13.7
11.61
10.63
12.77
10.8
Operating Margin (%)
- -
- -
- -
- -
- -
- -
2,703
2,609
1,808
2,223
2,467
1,814
2,027
2,093
2,422
2,250
2,538
Depreciation Expense
2,277
2,529
2,521
2,285
1,433
1,390
1,188
1,376
-967
1,222
3,239
2,970
2,491
2,412
1,638
2,258
1,490
Net Income, GAAP
26.83
26.34
26.34
27.21
27.13
27.04
26.15
- -
- -
34.21
27.05
28.34
27.53
27.37
27.52
27.63
27.96
Effective Tax Rate (%)
10.27
11.57
10.4
9.04
5.37
4.6
5.36
6.12
-4
4.6
10.86
10.98
8.8
7.58
4.71
6.46
4.2
Profit Margin (%)
4,935
5,241
3,070
4,029
1,630
3,880
3,896
2,292
4,143
4,630
7,643
4,459
7,113
3,462
3,115
4,185
2,880
Working Capital
11,411
15,121
13,163
13,566
14,378
16,006
15,914
4,962
7,378
7,068
7,687
3,495
5,031
4,960
8,280
8,922
8,975
LT Debt
13,248
14,636
15,200
16,560
18,694
19,593
20,916
19,806
19,655
20,973
21,486
25,176
30,453
30,403
33,210
29,493
29,018
Total Equity
10.32
10.54
9.71
9.11
7.68
6.24
4.76
- -
- -
5.79
11.68
10.12
8.48
7.14
6.47
7.6
6.86
Return on Invested Capital (%)
12.27
12.01
10.46
9.19
5.97
5.39
4.35
- -
- -
6.54
14.28
13.06
11.22
10.23
6.9
8.5
4.89
Return on Capital (%)
30.51
27.82
23.57
19.09
11.42
10.79
8.85
10.58
-8.19
10.66
24.63
18.99
13.98
12.39
8.1
10.73
7.47
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Dec'24
Mar'25
Jun'25
ST Debt
2,447
2,219
2,194
LT Borrowings
6,971
8,118
7,910
LT Finance Leases
1,309
1,145
1,065
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
272
272
272
Market Capitalization
49,449
58,777
51,669

Working Capital

FRC

•

in mil. unless spec.
Dec'24
Mar'25
Jun'25
Total Current Assets
18,162
18,164
15,733
Cash, Cash Equivalents & STI
2,961
4,203
1,945
Accounts Receivable, Net
6,348
5,265
4,785
Inventories
6,590
6,650
6,793
Total Current Liabilities
15,047
13,888
12,853
Payables & Accruals
- -
- -
- -
ST Debt
2,447
2,219
2,194
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
4.59%
7.2%
-11.19%
Free Cash Flow
23.52%
-2.52%
-19.37%
Net Income, GAAP
-25.21%
-4.37%
37.85%
Sales/Revenue/Turnover
2.2%
3.52%
0.6%
Total Cash Common Dividend
11.37%
28.22%
3.26%

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
7,513
8,305
7,870
11,071
34,759
2025
8,320
8,238
10,186
- -
34,968
2026
7,443
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
1.69
1.88
0.01
2.44
6.01
2025
1.1
1.92
3.19
- -
8.29
2026
1.47
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
4.44
0.02
0.04
4.5
2025
- -
4.62
0.01
- -
4.65
2026
- -
- -
- -
- -
- -
Similar Companies
Senzime AB (publ) (SEZI.ST)
Chordate Medical Holding AB (publ) (CMH.ST)
Delcath Systems, Inc. (DCTH)
Health Logic Interactive Inc. (CHYPF)
MicroTech Medical (Hangzhou) Co., Ltd. (2235.HK)
Adiuvo Investments S.A. (ADV.WA)
Business
Getinge AB (publ) Getinge AB (publ) develops, manufactures and markets medical equipment, systems and services for operating rooms, intensive care units, sterilization departments, cardiovascular procedures and life science applications to healthcare providers and life science institutions worldwide. The company operates through three main business areas including Acute Care Therapies, which provides life support solutions for critical conditions such as heart-lung machines, ventilators and monitoring systems; Surgical Workflows, which supplies operating tables, lights, sterile reprocessing equipment including washers, disinfectors and sterilizers, along with advanced IT systems for hospital efficiency and fluorescence imaging tools; and Life Science, which offers contamination control equipment, single-use solutions and biopharmaceutical production systems. Getinge AB (publ) sells its products in more than 135 countries and employs approximately 12,000 people. Founded in 1904 and headquartered in Gothenburg, Sweden, the company continues to expand through strategic acquisitions such as Paragonix Technologies in 2024 to bolster organ transplantation capabilities, Healthmark Industries, HPNE and Ultra Clean Systems in 2023 to strengthen sterile reprocessing and life science offerings, alongside a partnership with Zimmer Biomet announced in 2025 to support orthopedic procedures; it also reported record growth, high customer satisfaction and successful product launches across all areas in its 2024 annual report.